Eargo, Inc.

NasdaqGS:EAR Voorraadrapport

Marktkapitalisatie: US$53.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Eargo is gedaald met een gemiddeld jaarlijks percentage van -35.8%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.6%. De inkomsten zijn daalde met een gemiddeld percentage van 2.6% per jaar.

Belangrijke informatie

-35.84%

Groei van de winst

83.63%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.90%
Inkomstengroei-2.65%
Rendement op eigen vermogen-239.70%
Nettomarge-263.14%
Laatste winstupdate30 Sep 2023

Recente prestatie-updates uit het verleden

Recent updates

Seeking Alpha • Aug 30

Eargo: Straining To Be Heard

Summary Today, we take our first look at a small medical device company called Eargo, Inc. whose stock has slumped 90% over the past year. A good portion of the decline was caused by two key issues, both of which company management is hoping to put in the rearview mirror. An investment analysis follows in the paragraphs below. The art of conversation is the art of hearing as well as of being heard."― William Hazlitt Today, we put Eargo, Inc.(EAR) in the spotlight for the first time. This company has a variety of issues recently that have caused the stock to nosedive deep into 'Busted IPO' territory. Are brighter times on the horizon? An analysis follows below. Seeking Alpha Company Overview: Eargo, Inc. is a small medical device maker headquartered in San Jose, CA. The company markets and sells hearing aids through direct-to-consumer and through omni-channels. The stock currently has an approximate market capitalization of $75 million. The company launched the latest version of its hearing aid line, the Eargo 6 in January of this year. The Eargo 6 is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. June Company Presentation The company has been dogged by two major issues since it went public. The first was a criminal investigation initiated by the U.S. Department of Justice related to insurance reimbursement claims submitted by the company on behalf of its customers covered by the Federal Employee Health Benefits (FEHB) program. Management denied wrongdoing but settled this issue for $34.4 million in the Spring of this year. June Company Presentation Eargo also no longer accepted insurance as a method of direct payment in late 2021. In the second quarter of this year, Eargo operated on a cash-pay only basis which tanked sales (see section below). The company did get some very good news on this front two weeks ago as the FDA disclosed it would allow the sale of some hearing aids over the counter beginning in October. June Company Presentation The company has shipped over 110,000 hearing aid devices in its history and believes the market is significantly underpenetrated especially for its in-ear devices that offer several advantages to traditional hearing aids. June Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. The company had a GAAP loss of 78 cents a share as revenues plunged nearly 70% on a year-over-year basis to $7.25 million. Both top and bottom lines missed expectations badly. Returns rose to a third of sales from just less than a quarter in the same period a year ago. GAAP gross margin was 34.7%, compared to 71.8% in 2Q2021. Management stated via its earnings press release, the company would be focused on four key areas going forward. Eargo's omni-channel growth strategy Potentially regaining insurance coverage of Eargo for government employees under the FEHB program Refining and expanding the company's physical retail strategy Optimize the cash-pay business while continuing to invest in innovation. June Company Presentation Analyst Commentary & Balance Sheet: Wells Fargo ($10 price target), JPMorgan ($11 price target) and William Blair either maintained or downgraded Eargo to a Hold in the fourth quarter of 2021, but no analyst firms I can find have issued any ratings on Eargo so far in 2022. Just over one out of every ten shares are currently held short. Two insiders sold just over $40,000 in aggregate earlier this month. Another insider sold less than $15,000 worth of equity in March. That has been the only insider activity in Eargo's shares so far in 2022. The company ended the second quarter of the year with just over $106 million in cash and marketable securities on its balance sheet. This is almost entirely due to an issuance of $100 million senior secured convertible notes that occurred late in June. This is the core tranche of a $125 million strategic investment from Patient Square Capital. $16.2 million of these proceeds were used to pay off a previous debt obligation. Management will seek stockholder approval to increase the number of authorized shares and issue full potential amount of note conversion shares at its annual meeting in October of this year. If approved, this will consist of new shares of common stock created by a rights offering.
Seeking Alpha • Aug 16

Eargo jumps 77% following FDA rule on OTC hearing aids

Microcap Eargo (NASDAQ:EAR) closed up 77% on Tuesday following the U.S. FDA's announcement that it would allow the sale of some hearing aids over the counter beginning in October. Average daily volume for the company is ~4.2M shares. ~31.8M shares traded hands on Tuesday. Seeking Alpha's Quant Rating views Eargo (EAR) as a strong sell.
Seeking Alpha • Aug 08

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo press release (NASDAQ:EAR): Q2 Non-GAAP EPS of -$0.78 misses by $0.55. Revenue of $7.25M (-68.3% Y/Y) misses by $21.05M.
Seeking Alpha • Jul 05

Eargo completes $100M senior secured convertible notes issuance

Medical device company Eargo (NASDAQ:EAR) completed the issuance of $100M senior secured convertible notes to Patient Square Capital on Jun. 28. ~$16.3M of the net proceeds was used to repay all existing third-party indebtedness and related pay-off expenses. The remaining proceeds are intended to be used for working capital purposes and to fund general business requirements. Source: Press Release
Seeking Alpha • Dec 30

Eargo: A Binary Play On Hearing Loss

Eargo has exhibited stupendous sales growth in recent years and that looks set to continue. But this growth comes at the cost of significant cash outflows that have largely increased over time. The company's value is implied to be very small at this time, which could lead to significant upside if things go right. But significant risks definitely exist, making the company a binary prospect currently.
Seeking Alpha • Oct 08

Eargo Is A High Risk 'Option' With High Potential

Eargo Inc. is a US-based small-cap public company that manufactures and distributes Completely-In-Canal (CIC) hearing aids throughout the country. The company will be one of the beneficiaries of promoting sales of OTC hearing aids in the United States. Eargo Inc. has created a highly competitive product that meets high-quality standards at an affordable price.
Analyseartikel • Jul 10

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

In this article we are going to estimate the intrinsic value of Eargo, Inc. ( NASDAQ:EAR ) by estimating the company's...
Analyseartikel • Jan 16

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

If you want to know who really controls Eargo, Inc. ( NASDAQ:EAR ), then you'll have to look at the makeup of its share...

Opbrengsten en kosten

Hoe Eargo geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:EAR Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2341-1088819
30 Jun 2341-1419419
31 Mar 2340-14910218
31 Dec 2237-15710719
30 Sep 2234-15912123
30 Jun 224-18813925
31 Mar 2219-17514026
31 Dec 2132-15813625
30 Sep 2144-12411821
30 Jun 2185-459417
31 Mar 2179-327814
31 Dec 2069-307012
30 Sep 2057-326312
30 Jun 2047-445912
31 Mar 2038-475513
31 Dec 1933-444813
30 Sep 1930-424512
31 Dec 1823-343410
31 Dec 177-25155

Kwaliteitswinsten: EAR is momenteel verliesgevend.

Groeiende winstmarge: EAR is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EAR is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 35.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EAR over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EAR is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 14.8% ).

Rendement op eigen vermogen

Hoge ROE: EAR heeft een negatief Return on Equity ( -239.7% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/02/20 06:25
Aandelenkoers aan het einde van de dag2024/02/20 00:00
Inkomsten2023/09/30
Jaarlijkse inkomsten2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Eargo, Inc. wordt gevolgd door 4 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Robert HopkinsBofA Global Research
Robert MarcusJ.P. Morgan
Lawrence BiegelsenWells Fargo Securities, LLC